Sergey Sergeevich Masalskiy
Research Subjects
Sergey Sergeevich Masalskiy has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Smolkin Yuri Solomonovich Smolkin Yuri Solomonovich Smolkin Yuri Solomonovich
Academy of Postgraduate Education under FSBI FSCC of FMBA of Russia; State Budgetary Healthcare Institution of the Moscow Region “Research and Clinical Institute of Childhood of the Ministry of Health of the Moscow Region
10 shared publications - Liudmila Yur'EVna Barycheva
Stavropol State Medical University; Regional Children’s Clinical Hospital
4 shared publications - Elena V. Stezhkina
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
3 shared publications - Inna A. Larkova
Federal Research Center of Nutrition and Biotechnology
3 shared publications - Natal'Ya Viktorovna Shakhova
FSBEI HE ASMU MOH Russia
3 shared publications - Natalia Begievna Migacheva
Samara State Medical University
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Allergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Open AccessAllergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- Open Access
- 2 October 2025
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 94-114
Efficacy of the sublingual tablets for allergen-specific immunotherapy «Antypollin» in the treatment of allergic rhinitis caused by birch pollen
Introduction. Sublingual immunotherapy is administered using allergens that contain varying amounts of antigen. Different manufacturers employ distinct application regimens. The study investigates the efficacy of “Antypollin”, a low-dose sublingual tablet containing birch allergen 0.1–1000 PNU combined with ascorbic acid. Materials and Methods. An open-label, comparative non-randomized trial was conducted involving 52 participants. We evaluated the effectiveness of sublingual tablets of birch pollen extract (1000 PNU) in relation to seasonal variations in pollen concentrations when used according to pre-seasonal–seasonal protocols for patients with seasonal allergic rhinitis. Additionally, the allergenic potency of these tablets was assessed by comparing them with solutions having known characteristics. Results. Allergenicity testing was performed on 40 subjects using prick tests with a solution of 1000 PNU/mL, resulting in an average papule diameter of 4 [IQR: 3–5] mm. This corresponded to approximately 50,000 EAA (Russian Unit of allergen activity). Total cumulative dose over the course amounted to 24,667 PNU, with half being administered prior to peak season onset. Specifically, within the first 42 days, 667 PNU were delivered, followed by two phases from day 43 to 66 and again from day 67 to 90, each providing 12,000 PNU. During the birch pollen period between April 28th and May 11th, 2025, annual mean pollen concentrations ranged from 1000 to 2500 grains per cubic meter. In the treatment group receiving Antypollin tablets, the Visual Analog Scale (VAS) score for rhinitis symptoms showed significantly lower values compared to controls (median VAS scores: 2 [IQR: 1–5] versus 7 [IQR: 4–8]; p < 0.001). Similarly, the total symptom-medication score (TCS) demonstrated significant improvement (p = 0.001), with median values of 12.7 [IQR: 8.3–18.1] versus 22.8 [IQR: 17.0–28.3]. At peak pollen period (April 21–27th, 2025), pollen levels reached up to 14,500 grains per cubic meter. During this phase, while VAS symptom scores remained statistically different (5 [IQR: 3–6.5] vs. 7 [IQR: 5–8]; p < 0.01), the TCS did not achieve statistical significance (88%; median difference: 22.3 [IQR: 11.6–22.8] vs. 23.0 [IQR: 17.0–28.4]; p = 0.12). In contrast, during alder flowering periods characterized by lower pollen concentrations, weekly averaged median TCS scores in the Antypollin group were significantly reduced compared to control groups (10.6 [IQR: 5.9–14.1] vs. 14.9 [IQR: 14.7–19.4]; p = 0.01). Nasal and conjunctival symptoms differed markedly (6 vs. 9; p < 0.05), although medication usage only trended toward differences (3.43 vs. 9.71; p = 0.07). Symptom severity, measured via VAS, was halved relative to controls. Nasal complaints exhibited a 30 % reduction in median values (3 vs. 6), whereas ocular symptoms decreased by 33 % (3.5 vs. 5), though these results did not reach statistical significance (p ranging from 0.06 to 0.12). Conclusion. The study demonstrated that birch pollen tablets combined with ascorbic acid exhibit sufficient allergenicity and serve as an effective therapeutic agent under conditions where pollen concentrations approximate annual average levels. Patient complaint rates and medication consumption should be adequate for analysis of efficacy. After completing the first course of therapy, it was observed that high pollen concentrations elicit similar clinical manifestations in both the treatment and control groups. This indicates insufficient therapeutic effect following a single course. It is likely that more prolonged courses of maintenance therapy will be required to achieve sustainable immunotherapeutic outcomes.
- 2 October 2025
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 94-114
Open AccessEfficacy of the sublingual tablets for allergen-specific immunotherapy «Antypollin» in the treatment of allergic rhinitis caused by birch pollen
Introduction. Sublingual immunotherapy is administered using allergens that contain varying amounts of antigen. Different manufacturers employ distinct application regimens. The study investigates the efficacy of “Antypollin”, a low-dose sublingual tablet containing birch allergen 0.1–1000 PNU combined with ascorbic acid. Materials and Methods. An open-label, comparative non-randomized trial was conducted involving 52 participants. We evaluated the effectiveness of sublingual tablets of birch pollen extract (1000 PNU) in relation to seasonal variations in pollen concentrations when used according to pre-seasonal–seasonal protocols for patients with seasonal allergic rhinitis. Additionally, the allergenic potency of these tablets was assessed by comparing them with solutions having known characteristics. Results. Allergenicity testing was performed on 40 subjects using prick tests with a solution of 1000 PNU/mL, resulting in an average papule diameter of 4 [IQR: 3–5] mm. This corresponded to approximately 50,000 EAA (Russian Unit of allergen activity). Total cumulative dose over the course amounted to 24,667 PNU, with half being administered prior to peak season onset. Specifically, within the first 42 days, 667 PNU were delivered, followed by two phases from day 43 to 66 and again from day 67 to 90, each providing 12,000 PNU. During the birch pollen period between April 28th and May 11th, 2025, annual mean pollen concentrations ranged from 1000 to 2500 grains per cubic meter. In the treatment group receiving Antypollin tablets, the Visual Analog Scale (VAS) score for rhinitis symptoms showed significantly lower values compared to controls (median VAS scores: 2 [IQR: 1–5] versus 7 [IQR: 4–8]; p < 0.001). Similarly, the total symptom-medication score (TCS) demonstrated significant improvement (p = 0.001), with median values of 12.7 [IQR: 8.3–18.1] versus 22.8 [IQR: 17.0–28.3]. At peak pollen period (April 21–27th, 2025), pollen levels reached up to 14,500 grains per cubic meter. During this phase, while VAS symptom scores remained statistically different (5 [IQR: 3–6.5] vs. 7 [IQR: 5–8]; p < 0.01), the TCS did not achieve statistical significance (88%; median difference: 22.3 [IQR: 11.6–22.8] vs. 23.0 [IQR: 17.0–28.4]; p = 0.12). In contrast, during alder flowering periods characterized by lower pollen concentrations, weekly averaged median TCS scores in the Antypollin group were significantly reduced compared to control groups (10.6 [IQR: 5.9–14.1] vs. 14.9 [IQR: 14.7–19.4]; p = 0.01). Nasal and conjunctival symptoms differed markedly (6 vs. 9; p < 0.05), although medication usage only trended toward differences (3.43 vs. 9.71; p = 0.07). Symptom severity, measured via VAS, was halved relative to controls. Nasal complaints exhibited a 30 % reduction in median values (3 vs. 6), whereas ocular symptoms decreased by 33 % (3.5 vs. 5), though these results did not reach statistical significance (p ranging from 0.06 to 0.12). Conclusion. The study demonstrated that birch pollen tablets combined with ascorbic acid exhibit sufficient allergenicity and serve as an effective therapeutic agent under conditions where pollen concentrations approximate annual average levels. Patient complaint rates and medication consumption should be adequate for analysis of efficacy. After completing the first course of therapy, it was observed that high pollen concentrations elicit similar clinical manifestations in both the treatment and control groups. This indicates insufficient therapeutic effect following a single course. It is likely that more prolonged courses of maintenance therapy will be required to achieve sustainable immunotherapeutic outcomes.
- Open Access
- 11 June 2025
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 5-20
Adherence of doctors to clinical recommendations in the management of children and adolescents with allergic rhinitis
Introduction. The Russian Federation has adopted international and national conciliatory documents and clinical guidelines covering the diagnosis and treatment of allergic rhinitis (AR). The extent to which doctors adhere to the guidelines remains unclear.Methods: online survey of allergists (32.7%), pediatricians (54.4%) and others (total n = 364) in 2023–2024.Results: Most specialists (81.6%) adhere to Russian official clinical recommendation, while about 4% of respondents adhere to international guidelines. A significant part of doctors actively uses the term “seasonal/perennial” AR (75.3%), less often the indication of the severity and course of the disease is used. Pediatricians don’t use the classification more often than allergists. To determine the severity of the visual analog scale is used only in 23.0% of cases.Among laboratory diagnostic methods, allergists are more likely to prescribe a specific examination than pediatricians (87.8% vs. 56.8%). Only 53.8% of respondents consider it mandatory to conduct an allergological examination for patients with AR.57.4% of respondents believe that the amount of initial therapy depends on the severity of the disease. The most popular drugs for starting therapy are intranasal steroids (40.2%), antihistamines (23.5%), montelukast 4.0%, and intranasal antihistamines 4,8%. If it is necessary to use concomitant therapy 56.4% of doctors choose a fixed combination of intranasal steroid + antihistamines as a first-line therapy, and an additional 20.9% consider this option in rare cases. In severe cases, 16.9% of doctors prescribe oral steroids, 20.4% choose the parenteral route of corticosteroid administration, and 33.6% of respondents do not prescribe systemic corticosteroids. The majority of doctors surveyed are aware of the immunobiological therapy of AR — 73.0%, and 26.7% actively support the appointment of biological therapy for AR. Allergen-specific therapy is recommended to be considered by 61.9% of the surveyed doctors.Conclusion: The study shows the need to train physicians facing AR problems in accordance with current clinical guidelines and international practice.
- 11 June 2025
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 5-20
Open AccessAdherence of doctors to clinical recommendations in the management of children and adolescents with allergic rhinitis
Introduction. The Russian Federation has adopted international and national conciliatory documents and clinical guidelines covering the diagnosis and treatment of allergic rhinitis (AR). The extent to which doctors adhere to the guidelines remains unclear.Methods: online survey of allergists (32.7%), pediatricians (54.4%) and others (total n = 364) in 2023–2024.Results: Most specialists (81.6%) adhere to Russian official clinical recommendation, while about 4% of respondents adhere to international guidelines. A significant part of doctors actively uses the term “seasonal/perennial” AR (75.3%), less often the indication of the severity and course of the disease is used. Pediatricians don’t use the classification more often than allergists. To determine the severity of the visual analog scale is used only in 23.0% of cases.Among laboratory diagnostic methods, allergists are more likely to prescribe a specific examination than pediatricians (87.8% vs. 56.8%). Only 53.8% of respondents consider it mandatory to conduct an allergological examination for patients with AR.57.4% of respondents believe that the amount of initial therapy depends on the severity of the disease. The most popular drugs for starting therapy are intranasal steroids (40.2%), antihistamines (23.5%), montelukast 4.0%, and intranasal antihistamines 4,8%. If it is necessary to use concomitant therapy 56.4% of doctors choose a fixed combination of intranasal steroid + antihistamines as a first-line therapy, and an additional 20.9% consider this option in rare cases. In severe cases, 16.9% of doctors prescribe oral steroids, 20.4% choose the parenteral route of corticosteroid administration, and 33.6% of respondents do not prescribe systemic corticosteroids. The majority of doctors surveyed are aware of the immunobiological therapy of AR — 73.0%, and 26.7% actively support the appointment of biological therapy for AR. Allergen-specific therapy is recommended to be considered by 61.9% of the surveyed doctors.Conclusion: The study shows the need to train physicians facing AR problems in accordance with current clinical guidelines and international practice.
- Open Access
- 24 June 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2,p. 26-37
Evolution of standardization of therapeutic and diagnostic allergens produced in Russia
Allergen-specific immunotherapy is based on the development of induced tolerance in patients. Natural extracts are most often used as therapeutic allergens worldwide.The article presents new approaches to biological standardization of subcutaneous administered allergens. It is established that own standard allergens have specific allergenic activity, which was determined on sensitized patients-volunteers. The Russian Federation uses its own units — EAA (Units of Allergenic Activity). 100 000 EAA/mL corresponds to the size of wheal in prick test equal to 8 mm. The internal reference material (RM) of allergenic activity of pollen allergens ”Microgen“ have different specific activity depending on the type of allergen. The most common series have allergenic (specific) activity in the range of 150,000 — 200,000 EAA/mL.The control of the specific activity of allergen drugs is carried out in accordance with the current certified standard samples of the company’s standards. A method of competitive enzyme-linked immunosorbent assay using specific sera containing specific IgE antibodies is used for this purpose.In addition, the specific activity of allergen preparations is certified through three additional characteristics: total protein content (using the Bradford method), protein profile (through electrophoresis in a polyacrylamide gel with sodium dodecyl sulfate under reducing conditions), and authenticity through the presence of major specific components, which is determined by the Western blot method using sera containing IgE antibodies specific for the corresponding allergen.Currently, in the Russian Federation, the standardization of therapeutic and diagnostic allergens is conducted simultaneously according to two indicators: protein nitrogen content, expressed in Protein Nitrogen Units (PNU), and allergenic (specific) activity expressed in units of allergenic activity per milliliter (EAA/ml). While the PNU indicator partially reflects the allergenic properties of the drug, it does not fully capture these properties, making it necessary to remove PNU from the list of quality indicators for allergen medicines. This would require changes to regulatory documentation and instructions for allergens.When evaluating the allergenic activity of allergens, it is now recommended to focus on units of EAA. The consistency of the protein composition and presentation in the drug ensures increased safety and efficacy of therapy, as well as allows for comparison between drugs.
- 24 June 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2,p. 26-37
Open AccessEvolution of standardization of therapeutic and diagnostic allergens produced in Russia
Allergen-specific immunotherapy is based on the development of induced tolerance in patients. Natural extracts are most often used as therapeutic allergens worldwide.The article presents new approaches to biological standardization of subcutaneous administered allergens. It is established that own standard allergens have specific allergenic activity, which was determined on sensitized patients-volunteers. The Russian Federation uses its own units — EAA (Units of Allergenic Activity). 100 000 EAA/mL corresponds to the size of wheal in prick test equal to 8 mm. The internal reference material (RM) of allergenic activity of pollen allergens ”Microgen“ have different specific activity depending on the type of allergen. The most common series have allergenic (specific) activity in the range of 150,000 — 200,000 EAA/mL.The control of the specific activity of allergen drugs is carried out in accordance with the current certified standard samples of the company’s standards. A method of competitive enzyme-linked immunosorbent assay using specific sera containing specific IgE antibodies is used for this purpose.In addition, the specific activity of allergen preparations is certified through three additional characteristics: total protein content (using the Bradford method), protein profile (through electrophoresis in a polyacrylamide gel with sodium dodecyl sulfate under reducing conditions), and authenticity through the presence of major specific components, which is determined by the Western blot method using sera containing IgE antibodies specific for the corresponding allergen.Currently, in the Russian Federation, the standardization of therapeutic and diagnostic allergens is conducted simultaneously according to two indicators: protein nitrogen content, expressed in Protein Nitrogen Units (PNU), and allergenic (specific) activity expressed in units of allergenic activity per milliliter (EAA/ml). While the PNU indicator partially reflects the allergenic properties of the drug, it does not fully capture these properties, making it necessary to remove PNU from the list of quality indicators for allergen medicines. This would require changes to regulatory documentation and instructions for allergens.When evaluating the allergenic activity of allergens, it is now recommended to focus on units of EAA. The consistency of the protein composition and presentation in the drug ensures increased safety and efficacy of therapy, as well as allows for comparison between drugs.
- Open Access
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Open AccessAllergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- Open Access
- 9 October 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 34-57
The results of a survey of Russian doctors in order to identify the compliance of the management of children with chronic urticaria with clinical recommendations
Introduction. Primary observation of children with (CU) in Russia is performed by pediatricians, dermatologists, and algologists. It is unclear how clinical guidelines are used in a heterogeneous group of specialists.Materials and methods. Online survey of pediatricians, allergists, and dermatologists (n = 304) in the Russian Federation using a questionnaire, from 5 blocks of questions related to etiology, diagnosis, and therapy. 316 physicians with a median experience of 10 [5; 20] years were included in the questionnaire.Results. 83.3 % of respondents observed no more than 2 children with CU per month. Self-education to expand knowledge (video lectures, special literature) was indicated by 72.6 % of participants. The clinical guidelines used by physicians were documents of pediatric and allergy associations of Russia (77.3 and 55.9 %, respectively), international guides were used by 27 % of respondents.The most frequent deviations from the recommended algorithm were the prescription of biochemical blood tests (64.9 %), ultrasound examination of organs (56.9 %), consultations of specialists without indications: gastroenterologist (48.2 %), infectious disease specialist (31.8 %), rheumatologist (27.1 %). The autologous serum test in children is not used by 87.2 % of physicians for various reasons.During allergy testing, respondents recommend: the concentration of total IgE in serum (63.9 %), the number of eosinophils in the blood (61.2 %). The importance of determining specific IgE was indicated by no more than one third of the respondents. Skin tests during remission period were supported by 59.1 % of all physicians, who considered allergologic examination to be necessary. Diet: 18.6 % of respondents do not recommend a special diet for children; 27.7 % exclude from the diet foods to which sensitization is detected, the rest recommend an nonspecific elimination diet.Antihistamines of 2nd generation (AG II) are the most used in clinical practice (86.5 %). Physicians named cetirizine (25.7 %) and levocetirizine (19.7 %) as the drugs of choice up to 12 years of age. The need to double the dose of AG II in the absence of response to the standard dose was supported by 59.5 % of physicians. The other physicians preferred a change of AG II molecule in the standard dose. Experience with the use of omalizumab was reported by 20 % of specialists, with 76.3 % understanding the significance and willingness to use biologic therapy. If omalizumab is ineffective, 44.1 % of physicians consider glucocorticosteroids to be the drug of choice; 38.8 % — cyclosporine A. About one third of physicians use alternative therapies not considered in the clinical guidelines.Conclusion. A significant number of physicians do not use recommendations based on evidence-based studies in real practice. AG II are the basis of CU therapy in children in all age groups.
- 9 October 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3,p. 34-57
Open AccessThe results of a survey of Russian doctors in order to identify the compliance of the management of children with chronic urticaria with clinical recommendations
Introduction. Primary observation of children with (CU) in Russia is performed by pediatricians, dermatologists, and algologists. It is unclear how clinical guidelines are used in a heterogeneous group of specialists.Materials and methods. Online survey of pediatricians, allergists, and dermatologists (n = 304) in the Russian Federation using a questionnaire, from 5 blocks of questions related to etiology, diagnosis, and therapy. 316 physicians with a median experience of 10 [5; 20] years were included in the questionnaire.Results. 83.3 % of respondents observed no more than 2 children with CU per month. Self-education to expand knowledge (video lectures, special literature) was indicated by 72.6 % of participants. The clinical guidelines used by physicians were documents of pediatric and allergy associations of Russia (77.3 and 55.9 %, respectively), international guides were used by 27 % of respondents.The most frequent deviations from the recommended algorithm were the prescription of biochemical blood tests (64.9 %), ultrasound examination of organs (56.9 %), consultations of specialists without indications: gastroenterologist (48.2 %), infectious disease specialist (31.8 %), rheumatologist (27.1 %). The autologous serum test in children is not used by 87.2 % of physicians for various reasons.During allergy testing, respondents recommend: the concentration of total IgE in serum (63.9 %), the number of eosinophils in the blood (61.2 %). The importance of determining specific IgE was indicated by no more than one third of the respondents. Skin tests during remission period were supported by 59.1 % of all physicians, who considered allergologic examination to be necessary. Diet: 18.6 % of respondents do not recommend a special diet for children; 27.7 % exclude from the diet foods to which sensitization is detected, the rest recommend an nonspecific elimination diet.Antihistamines of 2nd generation (AG II) are the most used in clinical practice (86.5 %). Physicians named cetirizine (25.7 %) and levocetirizine (19.7 %) as the drugs of choice up to 12 years of age. The need to double the dose of AG II in the absence of response to the standard dose was supported by 59.5 % of physicians. The other physicians preferred a change of AG II molecule in the standard dose. Experience with the use of omalizumab was reported by 20 % of specialists, with 76.3 % understanding the significance and willingness to use biologic therapy. If omalizumab is ineffective, 44.1 % of physicians consider glucocorticosteroids to be the drug of choice; 38.8 % — cyclosporine A. About one third of physicians use alternative therapies not considered in the clinical guidelines.Conclusion. A significant number of physicians do not use recommendations based on evidence-based studies in real practice. AG II are the basis of CU therapy in children in all age groups.
- Open Access
- 17 July 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2,p. 16-32
Clinical and hardware evaluation of moisturizing properties and tolerability of a emollient cream with filagrinol (“Admera”) in atopic dermatitis in children
Objective. Evaluate the possibility of using a cream with 5 % filagrinol ("Admera") in children (0-18 years old) as an emollient in atopic dermatitis (AtD) and receive hardware measurements of skin hydration.Materials and methods. Open interventional study in parallel groups of children with AtD 0-18 years old (n = 72, median age 6 [3.75; 7.0] years). 2 equal groups: group 1 received methylprednisolone cream 1 time daily on lesions for 14 days + Admera emollient on the other skin; group 2 received the same treatment + cream with filagrinol 5 % applied from day 5 on the lesions.Results. Standard therapy with topical steroids and emollients was effective. The severity indices during steroid + emollient treatment decreased significantly: EASI 11.5 [6.0; 17.0] vs 2 [1; 3.8] scores, p < 0.001; skin lesion area from 17.5 % [10.0; 26.8 %] to 3.5 % [1.25; 6.0 %], p < 0.001; IGA score — 2 [2; 3] vs 1 [1; 2], p < 0.01.The total itching score for AtD (max 10) became significantly lower with therapy: nocturnal itching decreased from 3 [1; 7] to 1 [1; 3] and daytime itching from 4 [3; 7] to 2.5 [1; 4] points, p < 0.01.The mean values of hardware-measured skin hydration outside the lesion areas were 8 [6.0; 12.0] units at baseline. After 14 days of emollient, hydration of dry clear skin increased to 10 [8.0; 15.0] units (p = 0,017). The hydration of the skin on the affected areas increased significantly from 8 [6; 10] to 12.0 [8; 15] units (p = 0.001).The patients' organoleptic evaluation of the cream was 4.48 (max 5). No serious or moderate adverse events (AEs) were reported in this study. In 11.3 % of cases, the skin itching was detected, but resolved rapidly without treatment.Conclusion. The cream with 5 % filagrinol (“Admera”) significantly improved skin hydration, as measured instrumentally, in the area of dermatitis and dry skin without ones. The cream caused no significant adverse reactions and could be used together with topical steroids.
- 17 July 2023
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 2,p. 16-32
Open AccessClinical and hardware evaluation of moisturizing properties and tolerability of a emollient cream with filagrinol (“Admera”) in atopic dermatitis in children
Objective. Evaluate the possibility of using a cream with 5 % filagrinol ("Admera") in children (0-18 years old) as an emollient in atopic dermatitis (AtD) and receive hardware measurements of skin hydration.Materials and methods. Open interventional study in parallel groups of children with AtD 0-18 years old (n = 72, median age 6 [3.75; 7.0] years). 2 equal groups: group 1 received methylprednisolone cream 1 time daily on lesions for 14 days + Admera emollient on the other skin; group 2 received the same treatment + cream with filagrinol 5 % applied from day 5 on the lesions.Results. Standard therapy with topical steroids and emollients was effective. The severity indices during steroid + emollient treatment decreased significantly: EASI 11.5 [6.0; 17.0] vs 2 [1; 3.8] scores, p < 0.001; skin lesion area from 17.5 % [10.0; 26.8 %] to 3.5 % [1.25; 6.0 %], p < 0.001; IGA score — 2 [2; 3] vs 1 [1; 2], p < 0.01.The total itching score for AtD (max 10) became significantly lower with therapy: nocturnal itching decreased from 3 [1; 7] to 1 [1; 3] and daytime itching from 4 [3; 7] to 2.5 [1; 4] points, p < 0.01.The mean values of hardware-measured skin hydration outside the lesion areas were 8 [6.0; 12.0] units at baseline. After 14 days of emollient, hydration of dry clear skin increased to 10 [8.0; 15.0] units (p = 0,017). The hydration of the skin on the affected areas increased significantly from 8 [6; 10] to 12.0 [8; 15] units (p = 0.001).The patients' organoleptic evaluation of the cream was 4.48 (max 5). No serious or moderate adverse events (AEs) were reported in this study. In 11.3 % of cases, the skin itching was detected, but resolved rapidly without treatment.Conclusion. The cream with 5 % filagrinol (“Admera”) significantly improved skin hydration, as measured instrumentally, in the area of dermatitis and dry skin without ones. The cream caused no significant adverse reactions and could be used together with topical steroids.
- 7 October 2022
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 19 (3) , 299-316
Suppression spontaneous and induced expression of CD203c basophils after subcutaneous immunotherapy with ragweed and mugwort allergens
BACKGROUND: The basophil activation test (BAT) reflects the presence of immunoglobulin E on the cell surface and can be a tool for monitoring the effectiveness of allergen-specific immunotherapy. Spontaneous and allergen-induced BAT levels may likely change after effective subcutaneous immunotherapy, and this is of clinical importance. AIMS: To determine the basophil activation markers in patients sensitized to weed pollen during subcutaneous immunotherapy MATERIALS AND METHODS: This clinical study of 2 years included 60 patients with allergic rhinitis who underwent subcutaneous immunotherapy with weed allergens for two seasons. The proportion of basophil-expressing CD203c, spontaneously and after exposure to a trigger allergen, was determined. BAT was performed before treatment and after the first and second courses of preseason subcutaneous immunotherapy (0, 3, and 15 months of treatment). The effectiveness of subcutaneous immunotherapy was assessed by the dynamics of the symptom scale (Rhinoconjunctivitis total symptom score [RTSS]) and the drug assessment (Daily medical score [DMS]). RESULTS: Subcutaneous immunotherapy with watersalt extracts was effective. The median RTSS in patients after two courses decreased from 13.0 [10.0; 15.0] to 4.5 [3.00; 7.25] points (p 0.001) and DMS score from 2.0 [2.0; 2.0] to 1.0 [1.0; 2.0] points (p 0.001). Spontaneous BAT remained unchanged after the first course of allergen-specific immunotherapy. The mean BAT values before therapy and after the first course of subcutaneous immunotherapy did not differ (8.15% [6.10; 11.9] vs. 9.0% [6.30; 12.0]). The spontaneous BAT decreased after the second course of treatment (8.15% [6.10; 11.9] vs. 6.20% [4.27; 9.00], 2=15.5, p 0.001). Allergen-induced BAT significantly decreased from the first year of treatment. The overall change in the total group for BAT with ragweed after the first course of subcutaneous immunotherapy was 11.25% (95% confidence interval [CI]: 7.1015.10, p 0.001). The overall difference in the induced ВAT test at the end of therapy reached 8.63% (95% CI: 5.3012.05, p 0.001). The indices of induced BAT decreased by 12.0% after the first course of therapy with mugwort allergens (95% CI: 6.9517.90, p 0.001), and the difference from the initial values after the second course was 9.67% (95% CI: 6.8515.90, p 0.001). CONCLUSIONS: Subcutaneous immunotherapy with ragweed and mugwort allergens was effective. The change in spontaneous and induced BAT is associated with a positive effect of allergen-specific immunotherapy.
- 7 October 2022
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 19 (3) , 299-316
Suppression spontaneous and induced expression of CD203c basophils after subcutaneous immunotherapy with ragweed and mugwort allergens
BACKGROUND: The basophil activation test (BAT) reflects the presence of immunoglobulin E on the cell surface and can be a tool for monitoring the effectiveness of allergen-specific immunotherapy. Spontaneous and allergen-induced BAT levels may likely change after effective subcutaneous immunotherapy, and this is of clinical importance. AIMS: To determine the basophil activation markers in patients sensitized to weed pollen during subcutaneous immunotherapy MATERIALS AND METHODS: This clinical study of 2 years included 60 patients with allergic rhinitis who underwent subcutaneous immunotherapy with weed allergens for two seasons. The proportion of basophil-expressing CD203c, spontaneously and after exposure to a trigger allergen, was determined. BAT was performed before treatment and after the first and second courses of preseason subcutaneous immunotherapy (0, 3, and 15 months of treatment). The effectiveness of subcutaneous immunotherapy was assessed by the dynamics of the symptom scale (Rhinoconjunctivitis total symptom score [RTSS]) and the drug assessment (Daily medical score [DMS]). RESULTS: Subcutaneous immunotherapy with watersalt extracts was effective. The median RTSS in patients after two courses decreased from 13.0 [10.0; 15.0] to 4.5 [3.00; 7.25] points (p 0.001) and DMS score from 2.0 [2.0; 2.0] to 1.0 [1.0; 2.0] points (p 0.001). Spontaneous BAT remained unchanged after the first course of allergen-specific immunotherapy. The mean BAT values before therapy and after the first course of subcutaneous immunotherapy did not differ (8.15% [6.10; 11.9] vs. 9.0% [6.30; 12.0]). The spontaneous BAT decreased after the second course of treatment (8.15% [6.10; 11.9] vs. 6.20% [4.27; 9.00], 2=15.5, p 0.001). Allergen-induced BAT significantly decreased from the first year of treatment. The overall change in the total group for BAT with ragweed after the first course of subcutaneous immunotherapy was 11.25% (95% confidence interval [CI]: 7.1015.10, p 0.001). The overall difference in the induced ВAT test at the end of therapy reached 8.63% (95% CI: 5.3012.05, p 0.001). The indices of induced BAT decreased by 12.0% after the first course of therapy with mugwort allergens (95% CI: 6.9517.90, p 0.001), and the difference from the initial values after the second course was 9.67% (95% CI: 6.8515.90, p 0.001). CONCLUSIONS: Subcutaneous immunotherapy with ragweed and mugwort allergens was effective. The change in spontaneous and induced BAT is associated with a positive effect of allergen-specific immunotherapy.
- Open Access
- 20 September 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3
Clinical case of early debut of food allergy in a child up to 6 months
Introduction: It is believed that if the child ate only a cow’s milk formula (CMF), and сow's milk allergy is the only possible at the age of <6 months. This approach leads to erroneous treatment tactics. Presentation of the clinical case: a child aged 3 months with the debut of atopic dermatitis (AtD) of light degree (on the scale of the assessment of the researcher IGA 2). The patient was fed on artificial with a CMF from 1,5 months. Infant was examined at the place of residence. The CMF was changed to full hydrolysis CMF and without examination. Additionally, cosmetics were applied to the skin as needed. The child was examined by an allergologist after 3-4 weeks of diet. Negative dynamics were observed. Atopic dermatitis has become moderately severe with secondary infection complications (IGA 3, 50% affected skin). Prick-tests with allergens of milk, eggs, wheat, fish were carried out. High sensitization to egg and controversial to cow’s milk was found. The results were clarified during enzyme immunoassay: IgE ovomucoid – 0.78 IU/ml (norm <0.3 IU/ml); cow's milk 0.01 kUA/ l; casein – 0.01 kUA / l (norm <0.1 kUA/l). Considering the infected AtD, "hydrocortisone + natamycin + neomycin" 2 times a day was used in the therapy. Cosmetics on infected foci was canceled, while maintaining the treatment of dry unaffected skin. It is recommended to limit household contacts with eggs. After 2 weeks, the rash is residual (IGA 0-1). The cow’s milk formula was returned to the diet without exacerbations of the skin process. Conclusion: The case illustrates that sensitization in children can begin and be maintained without oral ingestion of the allergen. Sensitization at the age of up to 6 months is likely with a moderate – severe recurrent course of dermatitis. A specific allergological examination can be conduct with a developed disease at an early age. Skin tests and enzyme immunoassay are applicable in infants. The appointment of a diet without examination is unreasonable and should not be used.
- 20 September 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 3
Open AccessClinical case of early debut of food allergy in a child up to 6 months
Introduction: It is believed that if the child ate only a cow’s milk formula (CMF), and сow's milk allergy is the only possible at the age of <6 months. This approach leads to erroneous treatment tactics. Presentation of the clinical case: a child aged 3 months with the debut of atopic dermatitis (AtD) of light degree (on the scale of the assessment of the researcher IGA 2). The patient was fed on artificial with a CMF from 1,5 months. Infant was examined at the place of residence. The CMF was changed to full hydrolysis CMF and without examination. Additionally, cosmetics were applied to the skin as needed. The child was examined by an allergologist after 3-4 weeks of diet. Negative dynamics were observed. Atopic dermatitis has become moderately severe with secondary infection complications (IGA 3, 50% affected skin). Prick-tests with allergens of milk, eggs, wheat, fish were carried out. High sensitization to egg and controversial to cow’s milk was found. The results were clarified during enzyme immunoassay: IgE ovomucoid – 0.78 IU/ml (norm <0.3 IU/ml); cow's milk 0.01 kUA/ l; casein – 0.01 kUA / l (norm <0.1 kUA/l). Considering the infected AtD, "hydrocortisone + natamycin + neomycin" 2 times a day was used in the therapy. Cosmetics on infected foci was canceled, while maintaining the treatment of dry unaffected skin. It is recommended to limit household contacts with eggs. After 2 weeks, the rash is residual (IGA 0-1). The cow’s milk formula was returned to the diet without exacerbations of the skin process. Conclusion: The case illustrates that sensitization in children can begin and be maintained without oral ingestion of the allergen. Sensitization at the age of up to 6 months is likely with a moderate – severe recurrent course of dermatitis. A specific allergological examination can be conduct with a developed disease at an early age. Skin tests and enzyme immunoassay are applicable in infants. The appointment of a diet without examination is unreasonable and should not be used.
- Open Access
- 21 March 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1
Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
Background. In European countries, the prevalence of pollen sensitization reaches 30–40%. In Russia pollen allergy ranges from 12,7 to 38%. In the southern regions of Russia, the main one is ragweed and weed pollen. The efficacy of the subcutaneous medicinal ragweed allergen has not previously been evaluated using modern symptom scales. Methods. Open-label, single-center, placebo-uncontrolled study of 60 patients aged 16–55 years with allergic rhinitis in combination with bronchial asthma and without it. A 2-preseason course of AIT with a subcutaneous allergen of Ambrosia was used for patients with monosensitization and an allergen Ambrosia + Artemisia (for oligosensitized patients) and Ambrosia + a mix of pollen of causal allergen for polysensitized patients. Treatment started 4 months before and stopped 2–4 weeks before the beginning of pollination. The RTSS (the rhinoconjunctivitis total symptom score) scale was used to assess the symptoms, and the DMS (Daily medical score) was used to estimate of medical treatment. Results. After 1-st season of treatment, there was a rapid decrease in the RTSS to 5,0 [4,0; 9,0] compared to the initial values of 13 [10, 15] points. By the second year, the decline in RTSS amounted to 4,5 [3,0; 4,5] points (p <0,001), the total effect size by second course was 0,96 (strong effect of the intervention). DMS (before treatment) was 2,0 [2,0; 2,0] points, after the first and second courses — 1,0 [1,0; 2,0] points (p=0,002), with a moderate effect size of 0,67 after the first year; by the second year, the effect size is 0,75 versus baseline (p <0,01). Conclusion. Monotherapy with a subcutaneous ragweed allergen or its combination with other allergens show high effectiveness, starting from the first course of therapy. In the second year, the improvement continues, but the dynamics decreases. The study demonstrated a strong size of the effect of medical intervention, which cannot be explained by the placebo effect.
- 21 March 2022
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1
Open AccessEvaluation of the effectiveness of subcutaneous pollen weed polen allergens
Background. In European countries, the prevalence of pollen sensitization reaches 30–40%. In Russia pollen allergy ranges from 12,7 to 38%. In the southern regions of Russia, the main one is ragweed and weed pollen. The efficacy of the subcutaneous medicinal ragweed allergen has not previously been evaluated using modern symptom scales. Methods. Open-label, single-center, placebo-uncontrolled study of 60 patients aged 16–55 years with allergic rhinitis in combination with bronchial asthma and without it. A 2-preseason course of AIT with a subcutaneous allergen of Ambrosia was used for patients with monosensitization and an allergen Ambrosia + Artemisia (for oligosensitized patients) and Ambrosia + a mix of pollen of causal allergen for polysensitized patients. Treatment started 4 months before and stopped 2–4 weeks before the beginning of pollination. The RTSS (the rhinoconjunctivitis total symptom score) scale was used to assess the symptoms, and the DMS (Daily medical score) was used to estimate of medical treatment. Results. After 1-st season of treatment, there was a rapid decrease in the RTSS to 5,0 [4,0; 9,0] compared to the initial values of 13 [10, 15] points. By the second year, the decline in RTSS amounted to 4,5 [3,0; 4,5] points (p <0,001), the total effect size by second course was 0,96 (strong effect of the intervention). DMS (before treatment) was 2,0 [2,0; 2,0] points, after the first and second courses — 1,0 [1,0; 2,0] points (p=0,002), with a moderate effect size of 0,67 after the first year; by the second year, the effect size is 0,75 versus baseline (p <0,01). Conclusion. Monotherapy with a subcutaneous ragweed allergen or its combination with other allergens show high effectiveness, starting from the first course of therapy. In the second year, the improvement continues, but the dynamics decreases. The study demonstrated a strong size of the effect of medical intervention, which cannot be explained by the placebo effect.